Sinfonia Biotherapeutics
Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined orphan neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s and Parkinson’s disorders. Just as cancer is composed of many different subtypes, they know dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, they are developing breakthrough biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are known.
Industries
Nr. of Employees
small (1-50)
Products
SB0101
A biologic targeting neuropathic pain, particularly sciatica and painful diabetic neuropathy, by leveraging the natural reparative mechanism of Neublastin to repair injured sensory neurons and alleviate pain.
Gene Therapy Device Platform
A proprietary platform that delivers therapeutic proteins directly to the brain using minimally invasive surgery, with the ability to secrete multiple protein therapeutics simultaneously.
SB0201
A gene therapy device developed for the treatment of sensorineural hearing loss by targeting the sensory hair cells and nerve pathways of the inner ear.
SB0501
A gene therapy device designed to treat pharmacoresistant temporal lobe epilepsy by targeting affected anatomical structures and secreting antiepileptic biologics.
SB06Dx
A therapy aimed at restoring PGRN levels in the brain to halt or prevent the development of granulin-related frontotemporal dementia.
SB03Dx
A combinatorial therapeutic concept for GBA1-associated Parkinson’s disease that aims to rescue glucocerebrosidase function and restore the function of diseased neurons.
SB0101
A biologic targeting neuropathic pain, particularly sciatica and painful diabetic neuropathy, by leveraging the natural reparative mechanism of Neublastin to repair injured sensory neurons and alleviate pain.
Gene Therapy Device Platform
A proprietary platform that delivers therapeutic proteins directly to the brain using minimally invasive surgery, with the ability to secrete multiple protein therapeutics simultaneously.
SB0201
A gene therapy device developed for the treatment of sensorineural hearing loss by targeting the sensory hair cells and nerve pathways of the inner ear.
SB0501
A gene therapy device designed to treat pharmacoresistant temporal lobe epilepsy by targeting affected anatomical structures and secreting antiepileptic biologics.
SB06Dx
A therapy aimed at restoring PGRN levels in the brain to halt or prevent the development of granulin-related frontotemporal dementia.
SB03Dx
A combinatorial therapeutic concept for GBA1-associated Parkinson’s disease that aims to rescue glucocerebrosidase function and restore the function of diseased neurons.